Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Hutchison MediPharma Starts Clinical Trial of Second Cancer Drug

publication date: Feb 1, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hutchison MediPharma, the drug discovery arm of Chi-Med, has begun a Phase I trial of its second anti-angiogenesis cancer drug candidate, fruquintinib. The first molecule, sulfatinib (HMPL-012), began clinical trials in April of 2010. According to Hutchison, fruquintinib showed “potent” anti-angiogenesis activity in pre-clinical testing. More details....

Stock Symbol: (AIM: HCM)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors